Table 1.

Disease suppression by purified lipopeptide amendments against Fusarium yellows of tatsoi (10⁵ conidia mL⁻¹ pathogen inoculation)

(A) Iturin A treatments
Treatments	dpi
	7	8	9	10	11	12	13	14	15
Healthy control	0.0±0.0	0.0±0.0	0.0±0.0**	0.0±0.0**	0.0±0.0**	0.0±0.0**	0.0±0.0**	0.0±0.0**	0.0±0.0**
Disease control	0.0±0.0	0.1±0.06	0.5±0.1	0.6±0.2	0.9±0.2	1.4±0.2	1.4±0.2	1.7±0.3	1.9±0.3
0.12 mg L−1 iturin A	0.0±0.0	0.03±0.03	0.2±0.1*	0.2±0.1*	0.6±0.2	1.1±0.2	1.3±0.2	1.7±0.3	1.8±0.3
0.23 mg L−1 iturin A	0.0±0.0	0.1±0.06	0.4±0.1	0.6±0.1	1.0±0.2	1.4±0.2	1.7±0.2	1.8±0.2	2.0±0.2
0.47 mg L−1 iturin A	0.0±0.0	0.0±0.0	0.07±0.05**	0.07±0.05**	0.2±0.1**	0.4±0.1**	0.6±0.2*	0.8±0.2*	0.9±0.2**
0.94 mg L−1 iturin A	0.0±0.0	0.07±0.05	0.3±0.1	0.4±0.1	0.8±0.2	1.2±0.2	1.6±0.2	1.9±0.2	2.0±0.2
1.88 mg L−1 iturin A	0.0±0.0	0.03±0.03	0.2±0.07	0.2±0.1	0.8±0.2	1.1±0.2	1.5±0.2	2.0±0.2	2.0±0.2
3.75 mg L−1 iturin A	0.0±0.0	0.1±0.06	0.4±0.1	0.5±0.1	1.1±0.2	1.4±0.2	1.7±0.2	2.0±0.2	2.0±0.2
(B) Surfactin treatments
Treatments	dpi
	7	8	9	10	11	12	13	14	15
Healthy control	0.0±0.0	0.0±0.0	0.0±0.0	0.0±0.0**	0.0±0.0**	0.0±0.0**	0.0±0.0**	0.0±0.0**	0.0±0.0**
Disease control	0.0±0.0	0.0±0.0	0.03±0.03	0.4±0.1	1.0±0.2	1.6±0.2	2.1±0.2	2.3±0.2	2.5±0.2
0.12 mg L−1 surfactin	0.0±0.0	0.0±0.0	0.07±0.05	0.3±0.08	0.6±0.2	1.1±0.2	1.5±0.2	1.8±0.3	1.9±0.3
0.23 mg L−1 surfactin	0.0±0.0	0.0±0.0	0.1±0.05	0.2±0.1	0.4±0.1*	0.6±0.2**	1.0±0.2**	1.2±0.2**	1.5±0.3**
0.47 mg L−1 surfactin	0.0±0.0	0.0±0.0	0.1±0.06	0.5±0.1	1.0±0.2	1.4±0.3	1.7±0.3	1.8±0.3	2.0±0.3
0.94 mg L−1 surfactin	0.0±0.0	0.0±0.0	0.3±0.08	0.6±0.1	1.0±0.2	1.4±0.2	1.8±0.3	2.0±0.3	2.2±0.2
1.88 mg L−1 surfactin	0.0±0.0	0.0±0.0	0.2±0.08*	0.5±0.1	0.7±0.2	1.2±0.2	1.5±0.2	1.9±0.2	2.1±0.2
3.75 mg L−1 surfactin	0.0±0.0	0.0±0.0	0.2±0.08*	0.4±0.1	1.1±0.2	1.4±0.2	2.2±0.2	2.2±0.2	2.3±0.2

Mean ± SE of disease severity are represented.

^*significantly different at P<0.05 with Disease control by the Wilcoxon U-test;

^**significantly different at P<0.01 with Disease control by the Wilcoxon U-test